Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 644 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Girl’s New College Dorm Has Perfect View Of The Hospital Room... September 30, 2021 Immunotherapy is Beneficial in Gastric and Oesophageal Cancers, Studies Show [ESMO2020... September 21, 2020 African American Men More Likely to Die from Low-Grade Prostate Cancer January 28, 2019 Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic... May 12, 2021 Load more HOT NEWS PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable... Darolutamide Delays the Spread of Some Prostate Cancers The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable... Program Connects Adolescents and Young Adults to Quality Cancer Care
